A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled, Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients with Postbariatric Hypoglycemia

Trial Profile

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled, Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients with Postbariatric Hypoglycemia

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Exendin 9 (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Acronyms PREVENT
  • Most Recent Events

    • 09 Nov 2017 According to an Eiger BioPharmaceuticals media release, the company expects to initiate this study in 4Q 2017 and trial completion is anticipated in 2H 2018.
    • 07 Dec 2016 New trial record
    • 29 Nov 2016 According to an Eiger BioPharmaceuticals media release, company has filed an investigational new drug (IND) application with the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top